What is/are the significant challenges for vaccinating for FMD if there is an outbreak in the United States? (Choose one best answer.)

• A. Manufacturing and acquiring a large enough volume of FMD vaccine is a challenge since FMD vaccine is not manufactured in the United States.
• B. Vaccine strain selection is a challenge because there is no cross protection among the seven serotypes.
• C. Both having the appropriate vaccine strain and having enough of it available are significant challenges for plans to vaccinate if the U.S. has an outbreak of FMD.
• D. Because of the vaccine stockpile the significant challenges for vaccinating for FMD in an outbreak in the U.S. have been eliminated.

Answer: (C)

Vaccination during an FMD outbreak hinges on two practical bottlenecks: choosing a vaccine that actually protects against the circulating virus and ensuring there is enough vaccine to immunize a large number of animals quickly. FMD has multiple serotypes, and vaccines are serotype-specific with limited or no cross-protection across serotypes. That means using a vaccine strain that doesn’t match the outbreak serotype may leave animals unprotected, allowing the virus to spread. At the same time, even with the right strain, there may not be enough doses to cover all affected populations promptly. Production capacity, regulatory approvals, and distribution add further delays, so the response time can be critical. Therefore, plans must address both having an appropriate vaccine strain and having sufficient quantities available. The notion that vaccine stockpiles alone eliminate these challenges is inaccurate because strain matching and supply sufficiency, along with logistics and timing, remain essential considerations.